guardant reveal test | Guardant Reveal™: First Tissue-Free MRD Test

Keyword	CPC	PCC	Volume	Score	Length of keyword
guardant reveal test	0.29	0.3	5508	18	20
guardant	1.06	0.7	7451	30	8
reveal	1.08	0.6	7354	33	6
test	1.1	0.3	4294	84	4

Keyword	CPC	PCC	Volume	Score
guardant reveal test	0.84	0.8	103	83

Search Results related to guardant reveal test on Search Engine

Guardant Reveal™: First Tissue-Free MRD Test for CRC
guardantcomplete.com

https://www.guardantcomplete.com/products/guardant-reveal/

WebPatients. Blood-Based Screening. Annual Physician Notice. Advance Beneficiary Notice. Technical Information. Physician Insert. Guardant Reveal™ is the first tissue-free minimal residual disease (MRD) test for colorectal cancer. Available for breast & lung cancers. Results in 2 weeks.

DA: 79 PA: 97 MOZ Rank: 91

Tests for Patients with Early-stage Cancer - GuardantHealth
guardanthealth.com

https://guardanthealth.com/products/tests-for-patients-with-early-stage-cancer/

WebResidual disease detection and recurrence monitoring. Guardant Reveal™ is a revolutionary blood-only liquid biopsy test that detects circulating tumor DNA (ctDNA) for minimal residual disease (MRD) assessment in early …

DA: 44 PA: 40 MOZ Rank: 48

Guardant Reveal™ - Guardant Health AMEA
guardanthealthamea.com

https://www.guardanthealthamea.com/guardant-reveal/

WebGuardant Reveal TM is the first blood-only test that is able to detect residual and recurrent disease in two weeks, without the need for a tissue biopsy. The test detects circulating tumor DNA (ctDNA) in blood to inform treatment decisions after surgery and detect recurrence as well.

DA: 16 PA: 74 MOZ Rank: 62

IS MY CANCER GONE OR WILL MY CANCER RETURN?
mayo.edu

https://ce.mayo.edu/sites/default/files/media/2022-06/Guardant%20Reveal%20Patient%20Brochure.pdf

WebTo identify if there is MRD, Guardant Reveal looks for circulating tumor DNA (ctDNA) in your blood. The test result will indicate if this ctDNA has been found in your blood and may help your provider identify if there are additional tests needed to confirm if the cancer remains or has relapsed.

DA: 62 PA: 30 MOZ Rank: 61

Home - GuardantHealth
guardanthealth.com

https://guardanthealth.com/

WebOur commercially available tests help inform treatment decisions for patients with advanced cancer, monitor treatment response, detect residual and recurrent disease in patients with early-stage cancer, and soon may help screen for cancer before symptoms appear.

DA: 33 PA: 58 MOZ Rank: 45

Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test
guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Receives-Medicare-Coverage-for-Guardant-Reveal-Test/default.aspx

WebAug 2, 2022 · Guardant Reveal is a blood test that detects circulating tumor DNA (ctDNA) in blood after surgery to help oncologists identify cancer patients with residual or recurring disease who may benefit most from adjuvant therapy. It is the first blood-only liquid biopsy test available for MRD testing in patients with colorectal cancer (CRC).

DA: 35 PA: 69 MOZ Rank: 54

Guardant Health Launches Guardant Reveal™ Liquid Biopsy Test …
guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2021/Guardant-Health-Launches-Guardant-Reveal-Liquid-Biopsy-Test-for-Residual-Disease-and-Recurrence-Monitoring-in-Patients-with-Early-Stage-Colorectal-Cancer/default.aspx

WebFeb 16, 2021 · The Guardant Reveal test is Guardant Health’s first commercially available liquid biopsy test for clinical use in the management of early-stage cancer. The test will focus first on one indication where the unmet medical need exists, early-stage CRC, with additional cancer types to follow.

DA: 71 PA: 19 MOZ Rank: 81

What is Guardant Reveal? - Colontown University
colontown.org

https://learn.colontown.org/topic/test-reveal/

WebGuardant Reveal is a blood test for patients with colon or rectal cancer that can be ordered approximately one month after surgery to determine if there is remaining cancer in the body, or at the end of treatment (as part of regular surveillance) to help your doctor detect cancer recurrence (cancer coming back) early.

DA: 82 PA: 26 MOZ Rank: 26

Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test …
guardanthealth.com

https://investors.guardanthealth.com/press-releases/press-releases/2022/Guardant-Health-Expands-Use-of-Guardant-Reveal-Liquid-Biopsy-Test-for-Residual-Disease-Detection-and-Recurrence-Monitoring-to-Include-Early-Stage-Breast-and-Lung-Cancers/default.aspx

WebAug 15, 2022 · The Guardant Reveal blood test improves the management of early-stage cancer patients by detecting circulating tumor DNA (ctDNA) in blood after surgery—without the need for a tissue biopsy—to identify patients with minimal residual disease (MRD) who have a higher risk for recurrence and may benefit from additional therapy.

DA: 17 PA: 31 MOZ Rank: 85

Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test …
businesswire.com

https://www.businesswire.com/news/home/20220815005167/en/Guardant-Health-Expands-Use-of-Guardant-Reveal%E2%84%A2-Liquid-Biopsy-Test-for-Residual-Disease-Detection-and-Recurrence-Monitoring-to-Include-Early-Stage-Breast-and-Lung-Cancers

WebAug 15, 2022 · The Guardant Reveal blood test improves the management of early-stage cancer patients by detecting circulating tumor DNA (ctDNA) in blood after surgery—without the need for a tissue biopsy—to...

DA: 36 PA: 32 MOZ Rank: 50